Related Experiment Videos
[Three years experience with biological heart valve prostheses (author's transl)]
Thoraxchirurgie, Vaskulare Chirurgie
|August 1, 1978
Summary
Glutaraldehyde-fixed biological valves, including Hancock and Carpentier types, show a low rate of thrombotic complications (1.4%) in valve replacement surgery. These prostheses offer improved patient outcomes with minimal observed dysfunction.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Clinical Medicine
Context:
- Glutaraldehyde-fixed biological valves are increasingly used for aortic valve replacement.
- Hancock and Carpentier prostheses are common types implanted in patients.
- Clinical experience has driven the worldwide expansion of these valve types.
Purpose:
- To evaluate the clinical outcomes and complication rates of glutaraldehyde-fixed biological valves in patients undergoing valve replacement.
- To assess the incidence of thrombotic complications, hepatitis, and endocarditis.
- To determine the long-term efficacy and mechanical stability of these bioprostheses.
Summary:
- A study involving 290 patients (324 prostheses implanted) found a low thrombotic complication rate of 1.4% with glutaraldehyde-fixed aortic heterografts.
- Other postoperative complications included hepatitis (13.4%) and valvular endocarditis (1.5%).
- Improved clinical conditions were observed in 90.9% of patients, with no valve dysfunctions noted.
Impact:
- Glutaraldehyde-fixed biological valves demonstrate a favorable safety profile with low thrombotic complication rates.
- These bioprostheses contribute to improved clinical outcomes in patients requiring valve replacement surgery.
- Long-term studies are necessary to confirm the mechanical stability of these valves over several decades.